FI3413897T3 - Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn - Google Patents

Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn Download PDF

Info

Publication number
FI3413897T3
FI3413897T3 FIEP17706102.5T FI17706102T FI3413897T3 FI 3413897 T3 FI3413897 T3 FI 3413897T3 FI 17706102 T FI17706102 T FI 17706102T FI 3413897 T3 FI3413897 T3 FI 3413897T3
Authority
FI
Finland
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
use according
administration
Prior art date
Application number
FIEP17706102.5T
Other languages
English (en)
Finnish (fi)
Inventor
Daria Hazuda
Michael D Miller
Jay A Grobler
Deborah Anne Nicoll-Griffith
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Application granted granted Critical
Publication of FI3413897T3 publication Critical patent/FI3413897T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
FIEP17706102.5T 2016-02-12 2017-02-10 Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn FI3413897T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US201662297657P 2016-02-19 2016-02-19
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Publications (1)

Publication Number Publication Date
FI3413897T3 true FI3413897T3 (fi) 2023-08-25

Family

ID=58057333

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP17706102.5T FI3413897T3 (fi) 2016-02-12 2017-02-10 Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn

Country Status (37)

Country Link
US (4) US10537589B2 (https=)
EP (1) EP3413897B1 (https=)
JP (4) JP6810972B2 (https=)
KR (4) KR20220126787A (https=)
CN (2) CN113509480A (https=)
AU (3) AU2017217656B2 (https=)
BR (1) BR112018016349A2 (https=)
CA (1) CA3013473C (https=)
CL (1) CL2018002150A1 (https=)
DK (1) DK3413897T3 (https=)
DO (1) DOP2018000183A (https=)
EA (1) EA201891814A1 (https=)
ES (1) ES2953535T3 (https=)
FI (1) FI3413897T3 (https=)
GE (2) GEP20217231B (https=)
HR (1) HRP20230935T1 (https=)
HU (1) HUE063532T2 (https=)
IL (1) IL260874B2 (https=)
JO (1) JOP20170038B1 (https=)
LT (1) LT3413897T (https=)
MD (1) MD3413897T2 (https=)
MX (3) MX390604B (https=)
MY (1) MY197090A (https=)
NI (1) NI201800083A (https=)
NZ (1) NZ745065A (https=)
PH (1) PH12018501712A1 (https=)
PL (1) PL3413897T3 (https=)
PT (1) PT3413897T (https=)
RS (1) RS64448B1 (https=)
SG (1) SG11201806783WA (https=)
SI (1) SI3413897T1 (https=)
SV (1) SV2018005733A (https=)
TN (1) TN2018000267A1 (https=)
TW (2) TWI911551B (https=)
UA (1) UA126375C2 (https=)
WO (1) WO2017139519A1 (https=)
ZA (1) ZA201805073B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
EP3823632B1 (en) * 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
JP7530899B2 (ja) * 2018-12-20 2024-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Nrtti化合物の新規結晶形態
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
AU2020231934B2 (en) * 2019-03-06 2023-04-20 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
WO2021021717A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831852B1 (en) * 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
EA012844B1 (ru) 2003-02-19 2009-12-30 Йельский Университет Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
CN108289931B (zh) 2015-09-23 2022-10-11 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
KR102272235B1 (ko) * 2016-05-12 2021-07-01 머크 샤프 앤드 돔 코포레이션 항바이러스제의 전달을 위한 약물 전달 시스템
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
CA3150272A1 (en) * 2019-08-13 2021-02-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
CA3013473C (en) 2021-10-26
HRP20230935T1 (hr) 2023-11-24
MX2018009763A (es) 2018-11-29
US11337991B2 (en) 2022-05-24
HUE063532T2 (hu) 2024-01-28
US20250073254A1 (en) 2025-03-06
CN113509480A (zh) 2021-10-19
AU2022201686B2 (en) 2024-08-08
JP7559175B2 (ja) 2024-10-01
RS64448B1 (sr) 2023-09-29
SV2018005733A (es) 2018-12-14
AU2020202866A1 (en) 2020-05-21
JP6810972B2 (ja) 2021-01-13
CN108697727A (zh) 2018-10-23
GEAP202014873A (en) 2020-07-27
KR20210049201A (ko) 2021-05-04
TN2018000267A1 (en) 2020-01-16
AU2017217656B2 (en) 2020-01-30
DOP2018000183A (es) 2018-12-31
MD3413897T2 (ro) 2023-11-30
EA201891814A1 (ru) 2019-01-31
JP2021001189A (ja) 2021-01-07
WO2017139519A1 (en) 2017-08-17
IL260874B1 (en) 2023-06-01
US20220331350A1 (en) 2022-10-20
SG11201806783WA (en) 2018-09-27
KR20180108815A (ko) 2018-10-04
PT3413897T (pt) 2023-08-28
MY197090A (en) 2023-05-24
US12171776B2 (en) 2024-12-24
CA3013473A1 (en) 2017-08-17
ES2953535T3 (es) 2023-11-14
ZA201805073B (en) 2019-05-29
AU2020202866B2 (en) 2022-04-07
US10537589B2 (en) 2020-01-21
MX2022002925A (es) 2023-02-10
KR20250136420A (ko) 2025-09-16
LT3413897T (lt) 2023-08-25
NZ784982A (en) 2025-03-28
TWI822652B (zh) 2023-11-21
DK3413897T3 (da) 2023-09-18
HK1257347A1 (en) 2019-10-18
JP2022062170A (ja) 2022-04-19
PH12018501712A1 (en) 2019-05-15
NZ745065A (en) 2023-11-24
US20180055867A1 (en) 2018-03-01
JP7559175B6 (ja) 2024-10-22
JP2024001206A (ja) 2024-01-09
GEP20217231B (en) 2021-03-25
MX390604B (es) 2025-03-20
MX2022002924A (es) 2022-12-15
TWI911551B (zh) 2026-01-11
JOP20170038B1 (ar) 2021-08-17
IL260874B2 (en) 2023-10-01
CL2018002150A1 (es) 2018-12-14
NI201800083A (es) 2018-10-05
EP3413897A1 (en) 2018-12-19
IL260874A (https=) 2018-09-20
TW202417010A (zh) 2024-05-01
AU2022201686A1 (en) 2022-03-31
JP2019504857A (ja) 2019-02-21
KR102317570B1 (ko) 2021-10-25
GEP20207190B (en) 2020-12-10
AU2017217656A1 (en) 2018-08-23
PL3413897T3 (pl) 2023-10-02
US20200101098A1 (en) 2020-04-02
SI3413897T1 (sl) 2023-11-30
BR112018016349A2 (pt) 2018-12-26
TW201731514A (zh) 2017-09-16
JP7021314B2 (ja) 2022-02-16
KR20220126787A (ko) 2022-09-16
EP3413897B1 (en) 2023-06-14
UA126375C2 (uk) 2022-09-28

Similar Documents

Publication Publication Date Title
FI3413897T3 (fi) Menetelmiä hiv:n ja aids:n hoitoon ja ennaltaehkäisyyn
IL263110B (en) Combined treatment of notch and pd-1 or pd-l1 inhibitors
HRP20250480T1 (hr) Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
HRP20231018T1 (hr) Terapeutski spojevi korisni za profilaktičko ili terapijsko liječenje hiv virusne infekcije
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
JP2019516733A5 (https=)
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
JP2015529225A5 (https=)
NZ714963A (en) Compositions and methods for treating anemia
HRP20210901T1 (hr) Postupci pojačavanja tonične inhibicije i liječenja sekundarne nesanice
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
JP2016147915A5 (https=)
FI3307271T3 (fi) Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
UA96436C2 (ru) Долгосрочное лечение вич-инфекции
JP2021512149A5 (https=)
JP2017160178A5 (https=)
EP4650370A3 (en) Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
JP2017536408A5 (https=)
JP2022062170A5 (https=)
FI3355889T3 (fi) Diaminopyrimidiini-p2x3- ja p2x2/3-reseptorimodulaattoreita käytettäväksi yskän hoidossa
FI4212152T3 (fi) Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon
HRP20240309T1 (hr) Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid
RU2017116740A (ru) Комбинации для лечения рассеянного склероза